CHMP approves Roche Tecentriq combined caplatin and Abraxane chemotherapy for treatment of NSCLC adult patients

Roche recently announced that the EuropeanMedicines(http://Administration (CHMP) Recommended approval of its heavy immunotherapy Tecentriq combined caplatinum and Abraxane (albumin-combined yew alcohol, or nab-sequool) chemotherapy for first-line treatment of metastatic non-small cell lung cancer (NSCC) patients without EGFR or ALK-positive mutationsTo date, Tecentriq has been approved in more than 50 countries, including the European Union and the United States, for patients with metastatic NSCLC who have been treated in the past, as well as for patients with advanced local or metastatic urinary skin cancerThe recommendation is based on the Phase III IMpower130 study, a multi-center, open-label, randomized study that recruited 723 patients and was divided into Tecentriq combined caplatinand and nab-purple fir alcohol and caplating and caplatint-yew alcohol, and evaluated the efficacy and safety of Tecentriq-combined caplatinum and individual chemotherapy treatment phase IV scale non-SCLCC patientsThe results showed that the total survival of the Tecentriq treatment group was 18.6 months and the chemotherapy alone was 13.9 monthsThe treatment group also significantly reduced the risk of disease deterioration or death, with no progressive rebirth (PFS) of 7 months and 5.5 months of chemotherapy PFS alone, and Tecentriq combined with chemotherapy to help patients survive longer, with a median survival of 18.6 vs.13.9 months (HR-0.79; 95%CI: 0.64-0.98; p-0.033; Tecentriq combined with chemotherapy to significantly reduce disease deterioration or death risk by 36%, PFS median 7 months vs5.5 months (HR -0.64; 95% CI: 0.54-0.77; p-0.54-0.77; p 0.0001); Tecentriq combined with chemotherapy to reduce tumors with a total response rate (ORR) of 49.2% (95% CI: 44.49-53.96), compared with 31.9% (95% CI: 2) for chemotherapy alone 5.84-38.36); Median response duration was 8.4 months (95%, CI: 6.9-11.8) in patients in the treatment group, compared with 6.1 months (95% CI: 5.5-7.9) in patients with chemotherapy alone